Natera's Expansion in Cancer Recurrence Testing Attracts Investment from Wood's Ark
Biotechnology company Natera, with a market cap exceeding $28.4 billion, is gaining traction due to its leadership in measurable residual disease (MRD) testing for cancer recurrence detection. Its flagship product Signatera offers early and accurate identification of tumor DNA mutations post-removal, potentially revolutionizing treatment timelines. Wood's Ark has increased its stake following Natera’s progress toward FDA approval.
Topics: cancer recurrence tests FDA approval process market expansion MRD technology